Brentwood, TN – (Thursday, July 27, 2017) – PathGroup, one of the largest private providers of pathology and laboratory services in the Unites States, is pleased to announce that that Dr. Adam E. Meyer has joined the PathGroup team as the Associate Medical Director of Clinical Pathology Services.
Click HERE to see the full release
NASHVILLE (Tuesday, June 13, 2017) – Tennessee Gov. Bill Haslam, Department of Economic and Community Development Commissioner Bob Rolfe and PathGroup officials announced today that the pathology and clinical laboratory services company will undertake a major expansion in Middle Tennessee.
Please Click HERE to see the full release.
Brentwood, TN – (Thursday, February 16, 2017) – PathGroup, one of the largest private providers of pathology and laboratory services in the Unites States, is pleased to announce that Pranil K. Chandra, DO, FCAP, FASCP, Vice President and Chief Medical Officer and Medical Director, Genomic and Clinical Pathology Services at PathGroup, will speak at the 2017 Molecular Medicine Tri-Conference in San Francisco, CA on Monday, February 20, 2017.
Dr. Chandra’s session “Garnering Payer Support for Genomic Profiling by Demonstrating Clinical Utility” will review PathGroup’s experience with certain payers in garnering appropriate reimbursement for genomic profiling. In addition, he will review how to demonstrate clinical utility through illustrative examples highlighting diagnostic, prognostic, and/or therapeutic utility across hematologic and solid tumor malignancies.
For more information on the 2017 Molecular Medicine Tri-Conference please visit, http://www.triconference.com
- Enhanced cancer data and reporting standards for state cancer registries enable structured, real-time, data-driven decision making for cancer treatment specialists and patients
BRENTWOOD, Tenn., (Nov. 29, 2016) – PathGroup, one of the largest private providers of anatomic pathology and clinical lab services in the U.S., today announced a new partnership with the Centers for Disease Control and Prevention (CDC) and the California Department of Public Health that standardizes nationwide state cancer registry data and reporting, enabling physicians, surgeons and researchers to make data-driven treatment decisions with real-time information and analyses.
For Full Release, CLICK HERE
Brentwood, TENN - (November 11, 2016) – PathGroup, one of the largest private providers of pathology services in the Unites States, is pleased to be recognized by The Centers for Disease Control and Prevention (CDC) as the first national laboratory in the United States to standardize and structure cancer pathology and biomarker data reporting from its laboratory information system (LIS) to all state cancer registries.
PathGroup implemented standardized reporting in its proprietary system using the electronic Cancer Checklists (eCC) published by the College of American Pathologists (CAP). State cancer registries across the country will now electronically receive accurate and near real time cancer data.
Click Here to read the entire release from the CDC.
Dr. Pranil K. Chandra, Assistant Vice President and Medical Director of Molecular Pathology and Genomic Medicine Services at PathGroup, has co-authored a publication titled “The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer: A Report of the Association for Molecular Pathology”.
The Association of Molecular Pathology (AMP) report addresses the challenges in defining the clinical utility of molecular diagnostics for inherited disease and cancer, including molecular diagnostic procedures used for diagnosis, prognosis, risk assessment, prediction of future disease, and monitoring and selection of therapies of disease in patients. The report puts forth clinical utility definitions that appropriately recognize the contribution and value of molecular diagnostic testing to improve patient care.
The report has been released online ahead of publication in the September 2016 issue of The Journal of Molecular Diagnostics. Click Here to read the full manuscript.
Includes New Enhanced Lab Interface Exclusively for PathGroup and digiChart Clients
BRENTWOOD, TENN. – (April 8, 2016) – PathGroup, one of the largest private providers of pathology services in the United States, announced today a unique partnership with digiChart, one of the largest specialty-focused EHR providers in the women’s health space.
PathGroup and digiChart have partnered to develop a new ordering interface that will give the digiChart EHR product full bi-directional lab interface capabilities. PathGroup and digiChart clients will be able to both place orders and receive results through their existing digiChart EHR, creating a seamless process that will both save time in the office and simplify the lab ordering workflow for their practice. “PathGroup is committed to providing our clients with superior service. We have always been a leader in utilizing technology to deliver fast, accurate results and this partnership with digiChart adds ease of ordering for our mutual clients to that equation,” stated Dan Valenti, Senior Vice President and Chief Information Officer at PathGroup.
“As one of the largest providers of women’s health services in the United States, PathGroup wanted an EHR partner that showed that same commitment to women’s health providers. We felt that by working together, PathGroup and digiChart could significantly enhance and simplify the workflow for our mutual clients, helping them ultimately better serve their patients,” stated Richard Halstead, Executive Vice President and Chief Commercial Officer at PathGroup.
Built by OB/GYNs for OB/GYNs, digiChart’s specialty-focused EHR mimics the workflow in the OB/GYN practice, improves clinical decision-making, and provides unique functionality to enhance patient care. “This partnership with PathGroup significantly enhances our lab interface capabilities, allowing our clients’ offices to quickly and easily order and receive results for all their lab testing needs, directly in their digiChart EHR,” stated Rodney Hamilton, M.D., Chief Executive Officer at digiChart. digiChart also provides revenue cycle management tools that integrate seamlessly with the EHR, providing faster, more accurate processing of claims.
PathGroup and digiChart look forward to further enhancing the partnership with future collaborations, focused on ensuring clients have services that benefit both their practice and their patients.
About PathGroup
Founded in 1965, PathGroup has evolved into a premier provider of anatomic, clinical and molecular pathology services, as well as one of the largest providers of Women’s Health services in the United States. Privately held and physician centric, PathGroup works seamlessly with customers to provide superior diagnostic services – a vital link in the cycle of patient relationships. PathGroup uses the latest in proprietary and industry standard technology to deliver fast, accurate results. The company provides clients with the highest quality of services available, consistently exceeding the expectations of physicians, employees, payers and most importantly, patients. One Lab; Total Service. For more information, visit www.pathgroup.com.
About digiChart
digiChart offers specialized tools, services, and education to help OB/GYN practices compete with the larger practices or hospitals seeking to control more of the care continuum. Our tools deliver value clinically, operationally, and financially providing insight to know how to make the right changes to keep your practice on course. digiChart has expanded its offering to enhance the foundational EHR with new medical billing services and practice analytics to give OB/GYN practices the resources needed to succeed. Improving the Practice of Women’s Health. For more information, visit digiChart.com.
Contact:
Brent Sower
AVP Marketing
PathGroup
615.234.3908
bsower@pathgroup.com
Kathy Gill
VP Marketing and Communications
digiChart, Inc.
615.481.6646
kgill@digichart.com
Provides Newly Diagnosed Patients Genomic Baseline
BRENTWOOD, TENN. – (June 18, 2015) – PathGroup, one of the largest private providers of pathology services in the United States, announced today the launch of new cancer-specific SmartGenomics™ testing, expanding their genomic profiling menu for community-based oncologists. The addition of five diagnostic panels targeting cancers of lung, colon, brain, thyroid and melanoma/GIST represent testing options for newly diagnosed patients, the result of which will enable physicians to make more precise therapeutic recommendations and clinical management decisions.
PathGroup SmartGenomics uses multiple technologies to provide a complete genomic picture of a patient’s individual cancer. Each panel offers cost-effective, tailored genomic testing for its respective disease utilizing guideline recommendations from the National Comprehensive Cancer Network (NCCN). Standard of care diagnostic features include expanded RAS testing in colorectal cancer, biomarkers EGFR, ALK, ROS1, RET, MET in lung cancer, and BRAF, KIT mutation testing in melanoma.
“Genes that are relevant at diagnosis of lung cancer are not the same as those of melanoma or colon adenocarcinoma,” said Pranil K. Chandra, DO, Medical Director of Molecular Pathology Services at PathGroup. “PathGroup has profiled thousands of patients and we have found that the addition of diagnostic testing at biopsy via SmartGenomics and gold-standard technologies are true advances to our customers and ultimately our patients. As evidenced by the plethora of new and upcoming genomically-driven clinical trials, integrating genomic profiling into patient management and therapy selection is the future of clinical oncology practice and cancer pharmacotherapeutic development.”
Results from PathGroup’s cancer-specific panels provide treating clinicians with actionable information, linking the findings to available clinical trial options, therapies or both. Powered by the SmartGenomics platform, PathGroup offers comprehensive disease interrogation through all stages of cancer. The personalized medicine menu includes 62 and 85 gene panels for relapsed or refractory solid tumors and hematomalignancies, whole genome array analysis of greater than 22,000 genes, and disease-specific sequencing at initial diagnosis. With a best-in-class precision oncology suite, PathGroup provides a total lab solution for community-based oncologists from clinical to genomic.
Members of the oncology community have expressed an increased need for advanced testing earlier in the diagnostic-therapeutic continuum. Tennessee Oncology, one of the largest physician-owned oncology practices in the country, Chief Executive Officer Jeffrey F. Patton, MD, added, “When considering the likelihood of recurrence in many cancers, having a baseline of the most commonly altered pathways for each tumor allows us to determine what changes have occurred since initial diagnosis. Utilizing advanced genomic testing early in the cancer care continuum gives Tennessee Oncology physicians the ability to tailor treatments for each patient’s specific cancer.”
About PathGroup
Founded in 1965, PathGroup has evolved into a premier provider of anatomic, clinical and molecular pathology services. Privately held and physician centric, PathGroup works seamlessly with customers to provide superior diagnostic services – a vital link in the cycle of patient relationships. PathGroup uses the latest in proprietary and industry standard technology to deliver fast, accurate results. The company provides clients with the highest quality of services available, consistently exceeding the expectations of physicians, employees, payers and most importantly, patients. One Lab; Total Service. For more information, visit www.pathgroup.com
BRENTWOOD, Tenn. (August 5, 2014) – PathGroup, a leading provider of anatomic, clinical and molecular pathology services, and Cancer Clinics of Excellence (CCE), a national network of community-based oncology practices, is pleased to announce a newly formed partnership utilizing PathGroup’s versatile genomic profiling platform, SmartGenomics™, to further identify pharmacotherapeutic targets for patients within the CCE network.
For Full Release, please CLICK HERE
Thomson Reuters, PathGroup and GenoSpace collaborate to deliver advanced personalized medicine assays and reports to oncologists.
CAMBRIDGE, MA, – (May 8, 2014) — GenoSpace today announced that the company was named a Best of Show grand prize winner at the 2014 Bio-IT World Conference and Expo. GenoSpace for Clinical™ was recognized in the Web-Based Services and Software category for its comprehensive suite of offerings supporting genomic medicine.
Click Here to read the full article.